ZA963434B - Gene therapy using replication competent targeted adenoviral vectors. - Google Patents

Gene therapy using replication competent targeted adenoviral vectors.

Info

Publication number
ZA963434B
ZA963434B ZA9603434A ZA963434A ZA963434B ZA 963434 B ZA963434 B ZA 963434B ZA 9603434 A ZA9603434 A ZA 9603434A ZA 963434 A ZA963434 A ZA 963434A ZA 963434 B ZA963434 B ZA 963434B
Authority
ZA
South Africa
Prior art keywords
gene therapy
adenoviral vectors
replication competent
targeted adenoviral
targeted
Prior art date
Application number
ZA9603434A
Other languages
English (en)
Inventor
Richard J Gregory
Whei-Mei Huang
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23721566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA963434(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canji Inc filed Critical Canji Inc
Publication of ZA963434B publication Critical patent/ZA963434B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9603434A 1995-05-03 1996-04-30 Gene therapy using replication competent targeted adenoviral vectors. ZA963434B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/433,798 US20030026789A1 (en) 1995-05-03 1995-05-03 Gene therapy using replication competent targeted adenoviral vectors

Publications (1)

Publication Number Publication Date
ZA963434B true ZA963434B (en) 1997-02-03

Family

ID=23721566

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9603434A ZA963434B (en) 1995-05-03 1996-04-30 Gene therapy using replication competent targeted adenoviral vectors.

Country Status (8)

Country Link
US (4) US20030026789A1 (es)
EP (1) EP0827546A2 (es)
JP (1) JPH11506315A (es)
AR (1) AR001830A1 (es)
AU (1) AU5723696A (es)
CA (1) CA2218390A1 (es)
WO (1) WO1996034969A2 (es)
ZA (1) ZA963434B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
AU745600B2 (en) * 1997-03-03 2002-03-21 Cell Genesys, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
EP1905837A1 (en) * 1997-03-03 2008-04-02 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
AU744725B2 (en) * 1997-03-03 2002-02-28 Cold Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1998039467A2 (en) * 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
US6432700B1 (en) * 1997-03-03 2002-08-13 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
EP1012259B1 (en) 1997-06-04 2009-09-30 Oxford Biomedica (UK) Limited Tumor targeted vector
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
EP0945507A1 (de) * 1998-03-27 1999-09-29 Boehringer Mannheim Gmbh Tumorspezifische Expressionskontrollregion und deren Verwendung
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6410313B1 (en) * 1998-10-01 2002-06-25 University Of Southern California Gene delivery system and methods of use
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
ATE275629T1 (de) 1999-04-02 2004-09-15 Hisamitsu Pharmaceutical Co Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
WO2000067576A1 (en) * 1999-05-12 2000-11-16 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
WO2001023004A1 (en) * 1999-09-30 2001-04-05 The Trustees Of The University Of Pennsylvania Replication selective adenoviruses for use in cancer therapy
US7396679B2 (en) * 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
CA2380537C (en) * 1999-11-15 2011-01-18 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
AU1290001A (en) 1999-11-18 2001-05-30 Oxford Biomedica (Uk) Limited Antibodies
US7048920B2 (en) * 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US7109029B2 (en) 2001-02-23 2006-09-19 Cell Genesys, Inc. Vector constructs
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
GB0117198D0 (en) * 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
US7364727B2 (en) * 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
US7371570B2 (en) 2002-11-01 2008-05-13 Cell Genesys, Inc. Cell-specific adenovirus vector comprising EBV-specific promoter
US20050097066A1 (en) * 2003-10-31 2005-05-05 Pitney Bowes Incorporated Method and system for a mailing machine to verify the integrity of printed postage
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
AU2009303690B2 (en) 2008-09-26 2014-06-19 Tocagen Inc. Gene therapy vectors and cytosine deaminases
US9669049B2 (en) 2010-10-31 2017-06-06 Tocagen Inc. Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders
KR101488395B1 (ko) 2011-01-26 2015-04-29 연세대학교 산학협력단 암세포 특이적 유전자 발현을 위한 재조합 유전자발현 조절서열
CN102796709A (zh) * 2011-05-27 2012-11-28 中国科学院上海生命科学研究院 肝癌特异性基因-病毒及其应用
CN102813939A (zh) * 2011-06-10 2012-12-12 中国科学院上海生命科学研究院 前列腺癌特异性基因-病毒药物
SG10201913784YA (en) 2012-01-25 2020-03-30 Dnatrix Inc Biomarkers and combination therapies using oncolytic virus and immunomodulation
AU2013214776B2 (en) 2012-02-02 2017-11-09 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
WO2017040815A1 (en) 2015-09-04 2017-03-09 Tocagen Inc. Recombinant vectors comprising 2a peptide
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE178490T1 (de) * 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
DE69434594T2 (de) * 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US5728379A (en) * 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
AU716045B2 (en) * 1994-11-28 2000-02-17 Genetic Therapy, Inc. Vectors for tissue-specific replication

Also Published As

Publication number Publication date
CA2218390A1 (en) 1996-11-07
JPH11506315A (ja) 1999-06-08
AU5723696A (en) 1996-11-21
EP0827546A2 (en) 1998-03-11
US20070254357A1 (en) 2007-11-01
US20030026789A1 (en) 2003-02-06
WO1996034969A2 (en) 1996-11-07
AR001830A1 (es) 1997-12-10
US20010053768A1 (en) 2001-12-20
WO1996034969A3 (en) 1997-02-13
US20050002906A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
ZA961587B (en) Gene transfer-mediated angiogenesis therapy
IL117309A0 (en) Gene transfer-mediated angiogenesis therapy
AU4787697A (en) Therapeutic gene
ZA987844B (en) Therapeutic combinations.
EP0633943A4 (en) GENTHERAPY USING TARGETED VIRAL VECTORS.
ZA987839B (en) Combination therapy.
AU3972893A (en) Gene therapy using the intestine
AU2552795A (en) Safe vectors for gene therapy
EP0789592A4 (en) GENE EYE THERAPY
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
ZA9711029B (en) Therapeutic agents.
AU3737297A (en) Bacteriophage-mediated gene therapy
IL117691A0 (en) Gene transfer into the kidney
AU3169495A (en) Gene therapy for restenosis using an adenoviral vector
AU4770297A (en) Receptor-mediated gene transfer system for targeting tumor gene therapy
ZA971272B (en) Gene expression.
AU1184399A (en) Therapeutic molecules
AU4401297A (en) Improved retroviral vectors for gene therapy
ZA965494B (en) Therapeutic agents.
AU4941096A (en) Self-deleting vectors for gene therapy
AU3036197A (en) Adenovirus vectors for gene therapy
AU1991899A (en) Molecules associated with the human fused gene
GB9521711D0 (en) Gene therapy
GB9520433D0 (en) Gene therapy